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ABSTRACT (200 words) 26 
In the twenty years since human embryonic stem cells, and subsequently induced pluripotent stem 27 
cells (collectively, pluripotent stem cells), were first described, it has become apparent that these 28 
cells may acquire genetic changes during long term culture, commonly manifest by gains or losses 29 
of particular chromosomal regions, or by mutations in certain cancer associated genes, especially 30 
TP53.  Such changes raise concerns for the safety of products destined for clinical applications in 31 
regenerative medicine.  Although acquired changes may not be present in a cell line at the start of a 32 
research program, the low sensitivity of current detection methods means that mutations may be 33 
difficult to detect if they arise but are only present in a small proportion of the cells.  Nevertheless, 34 
recent work suggests that the underlying mutation rate in pluripotent stem cells is low, though they 35 
also seem to be particularly susceptible to genomic damage.  This apparent contradiction can be 36 
reconciled by the observations that, in contrast to somatic cells, pluripotent stem cells are 37 
programmed to die in response to genomic damage, which may reflect the requirements of early 38 
embryogenesis.  Thus, the common variants that do occur are likely rare events that offer the cells 39 
a selective growth advantage. 40 
 41 
INTRODUCTION 42 
Although little more than 20 years has passed since the first human embryonic stem cells (ESC) 43 
were reported (Thomson et al., 1998, Reubinoff et al., 2000), and less than 14 years since human 44 
induced pluripotent cells (iPSC) were described (Takahashi et al., 2007, Yu et al., 2007), clinical 45 
trials for regenerative medicine using derivatives of these cells are already underway or on the 46 
horizon (da Cruz et al., 2018, Schwartz et al., 2012, Song et al., 2015, Mandai et al., 2017, Barker 47 
et al., 2017).  Yet over this period it has become evident that both human ESC and iPSC (collectively 48 
here denoted as PSC), although mostly diploid when first derived, may acquire genetic alterations, 49 
ranging from large scale structural modifications readily recognized as karyotypic variants through 50 
to single base pair changes on subsequent passage (Figure 1).  Although not the focus of this 51 
review, it is worth noting that epigenetic changes encompassing aberrations in DNA methylation, 52 
imprinting and X-chromosome inactivation have also been reported in PSC (reviewed in Bar and 53 
Benvenisty, 2019).  The observation of genetic and epigenetic changes in PSC has triggered worries 54 
about the significance of such variants for the safety of PSC-based regenerative medicine (Yasuda 55 
et al., 2018, Sato et al., 2019).  In particular, some recurrent genetic changes, for example mutations 56 
in TP53, or gains of chromosome 12p, 17q, and 20q have been associated with various cancers, 57 
notably the association of gain of chromosome 12p with embryonal carcinoma (EC) cells, the 58 
malignant counterpart of PSC (Andrews, 2002).  Indeed, a planned trial of iPSC-derived retinal 59 
pigment cells to treat age related macular degeneration was halted when a point mutation was 60 
detected, although whether this particular mutation may have caused a problem was unknown 61 
(Mandai et al., 2017, Garber, 2015). 62 
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Some of the genetic variants found in PSC may well have been present in the embryos or somatic 63 
cells from which they were derived, or may have been induced during derivation (Hussein et al., 64 
2011, Rouhani et al., 2016).  The outcomes of the currently pursued in-depth studies into the effect 65 
of the choice of a starting cell type and a method of reprogramming on the overall mutational burden 66 
in iPSC (reviewed in Steichen et al., 2019) will have an important bearing on the practical applications 67 
of PSC. However, regardless of their ultimate findings, a key feature of such ‘Mutations of Origin’ is 68 
that they will be present in all the cells of a given PSC line and so should be readily detectable and 69 
assessed for their significance before research with a particular line is initiated.  Much more 70 
problematic, and the subject of this review, are mutations that were not present initially but arise, 71 
often recurrently, during culture of the cells – ‘Acquired Mutations’.  Nevertheless, it is important to 72 
view these variants in perspective: many PSC lines do not acquire the commonly observed variants, 73 
or only in late passage.  In a study by the International Stem Cell Initiative, 79 lines out of 122 retained 74 
a normal karyotype (Amps et al., 2011).  In another study, recurrent mutants of TP53 were detected 75 
in only five out of 140 human PSC lines (Merkle et al., 2017).  On the other hand, since the sensitivity 76 
of detecting mutant cells in a mosaic culture is low (see BOX 1), such variant cells may lurk in 77 
cultures for a considerable time until they take over due to a selective growth advantage, or the line 78 
is subject to a population bottleneck.  Further, some variants, for example gains of a small region of 79 
the long arm of chromosome 20, are particularly difficult to detect by G-banding karyotyping and may 80 
go unnoticed, even when present in a substantial proportion of the cells (Amps et al., 2011). 81 
Over the years, many studies have sought to find ways to minimize the appearance of genetic 82 
variants in PSC.  However, in such quests, it is important to recall that the appearance of the common 83 
recurrent variants depends upon two independent events, mutation followed by subsequent 84 
selection (Figure 1), and these can be experimentally difficult to disentangle.  The mechanisms of 85 
selective growth advantage, due to the altered expression or activity of one or more genes (‘Driver’ 86 
genes), or to the effects of culture conditions on selection, can be relatively easily analysed by spiking 87 
wild type cultures with variant cells and monitoring their subsequent growth patterns (Olariu et al., 88 
2010).  By contrast, mutation occurs at a very low frequency so that mutations are difficult to monitor 89 
directly without expansion of the variant cells, in which case the estimates of mutation rate may be 90 
compromised by selection unless this is avoided by often cumbersome clonogenic strategies 91 
(Thompson et al., 2020).   92 
In this review we discuss the nature of the acquired genetic variants that commonly arise during 93 
culture of human PSC cultures and consider the potential consequences of acquired genetic variants 94 
in human PSC, both for research and for clinical applications.  We then discuss the mechanisms of 95 
selective growth advantage that lead to the recurrent appearance of particular variants.  Finally, we 96 
focus on the underlying mechanisms of mutation in PSC; it seems that PSC differ substantially from 97 
somatic cells in both their susceptibility and response to DNA damage, which may reflect the 98 




ACQUIRED GENETIC VARIATION 101 
Karyotypic abnormalities 102 
Traditionally, routine screening of PSC lines for the identification of genetic changes has been 103 
performed mainly by cytogenetic and molecular methods that are capable of detecting numerical 104 
and structural aneuploidies rather than DNA sequence changes (Draper et al., 2004, Amps et al., 105 
2011).  Consequently, karyotypic abnormalities are the most comprehensively catalogued genetic 106 
changes in PSC to date.  In taking stock of the reports of karyotypic abnormalities in PSC over the 107 
last two decades, it is clear that the aberrant PSC karyotypes can encompass virtually any type of 108 
an abnormality, including numerical aneuploidies, such as a whole chromosome gain (trisomy) or 109 
loss (monosomy), as well as structural aneuploidies, including interstitial duplications, deletions, 110 
inversions, amplifications and translocations (Draper et al., 2004, Amps et al., 2011, Taapken et al., 111 
2011).  That said, the distribution of chromosomal aberrations appears to be non-random and certain 112 
types of variants are more commonly seen (Taapken et al., 2011, Draper et al., 2004, Amps et al., 113 
2011, Baker et al., 2016).  The first apparent bias is towards gains rather than losses of chromosomal 114 
material.  Indeed, it is estimated that over 70% of all karyotypic abnormalities reported in ESC 115 
represent whole or partial chromosome gains, whereas only around 20% of reported abnormalities 116 
are losses of chromosomes or chromosomal material (Baker et al., 2016).  Losses of entire 117 
chromosomes are particularly rare, representing only around 2% of reported abnormalities in PSC 118 
cultures (Baker et al., 2016).  The under representation of monosomies in PSC concurs with the 119 
observation that cells in general tolerate gains of genetic material more readily than losses (Torres 120 
et al., 2008).  Both unbalanced and balanced translocations, i.e. with or without the overt net gain or 121 
loss of chromosomal material, respectively, have also been reported, but unlike in certain 122 
haematological malignancies, for example, no common recurrent translocations or fusion genes 123 
have so far been associated with variant PSC (Draper et al., 2004, Amps et al., 2011, Baker et al., 124 
2016, Assou et al., 2020).  On the other hand, some chromosomes are rarely, if ever, reported as 125 
gained or lost in PSC, including chromosomes 2, 4, 19 and 21 (Amps et al., 2011, Baker et al., 2016).  126 
Finally, most striking is the observation of a consistent pattern of chromosomes affected by 127 
aneuploidy in PSC, with the majority of detected aberrations in PSC karyotypes representing gains 128 
of the whole or fragments of chromosomes 1, 12, 17, 20 and X (Baker et al., 2007, Amps et al., 2011, 129 
Nguyen et al., 2013, Baker et al., 2016, Assou et al., 2020) (Box 2).  Of these, a particularly insidious 130 
change is the frequent gain of a small, variable region of located near the centromere of the long 131 
arm of chromosome 20 (Lefort et al., 2008, Spits et al., 2008).  Often this gain is below the resolution 132 
of G-band karyotyping but, for example, it was noted by SNP array analysis in over 20% of the cell 133 
lines in the ISCI study (Amps et al., 2011, Baker et al., 2016).  That the same repertoire of 134 
aneuploidies is observed across different ESC and iPSC lines and across different laboratories 135 
world-wide (Amps et al., 2011) points to the enhanced fitness of such variant cells, likely due to an 136 
5 
 
increased expression of one or more of the genes located on amplified chromosomes (Enver et al., 137 
2005, Ben-David et al., 2014). 138 
 139 
Point mutations 140 
Point mutation screening has not yet become routine in PSC maintenance and, therefore, culture 141 
acquired nucleotide changes in these cells remain largely unexplored.  A couple of, recent studies 142 
have investigated the presence and potential recurrence of cancer-related point mutations in PSC.  143 
Merkle et al.  (Merkle et al., 2017) subjected the DNA from 140 ESC lines provided by different 144 
laboratories world-wide to whole exome sequencing.  After filtering out inherited polymorphisms and 145 
focusing only on variants that were present in a subset of cells, as suspected culture-acquired 146 
mutations, 28 of the 263 mosaic variants detected across the 140 lines were predicted to alter gene 147 
function.  Of these, the tumor suppressor gene TP53 was the only gene in which mutations were 148 
detected in multiple cell lines, with six different missense mutations in five independent ESC lines.  149 
All of the identified TP53 missense mutations affected cytosines of highly mutable CpG dinucleotides 150 
within four of the residues encoding the DNA-binding domain of the TP53 protein, therefore rendering 151 
the mutant TP53 protein inactive.  Further TP53 mutations in both ESC and iPSC were uncovered 152 
by leveraging RNA-sequencing datasets from public repositories (Merkle et al., 2017, Avior et al., 153 
2019), thereby establishing TP53 as a recurrently mutated gene in PSC.  As the observed TP53 154 
mutations represent some of the most frequent mutations in cancer (Kandoth et al., 2013) and are 155 
also known to cause a familial cancer predisposition disorder, the Li-Fraumeni syndrome (Malkin et 156 
al., 1990, Srivastava et al., 1990), these findings have brought into focus the need for monitoring of 157 
PSC for culture-acquired TP53 mutations. 158 
Despite being the most prevalent, TP53 mutations are not the only recurrent point mutations arising 159 
in cancer-related genes upon PSC expansion (Avior et al., 2019).  Recently, recurrent point 160 
mutations were detected in at least 22 other genes that were previously classified within the COSMIC 161 
Census database as genes with a documented cancer-related activity, including CCND2, PCM1, 162 
MYH9, HIF1A, BCL9 and VHL (Avior et al., 2019).  Intriguingly, the mutational burden seems to differ 163 
between different pluripotent states; human PSC in the naïve state, representing the pluripotent state 164 
of the pre-implantation epiblast cells (Nichols and Smith, 2009), were estimated to carry four times 165 
more mutations than their primed counterparts, which correspond to the pluripotent state of the post-166 
implantation epiblast (Avior et al., 2019).  As the naïve samples analysed in this study were reset 167 
from primed PSC, rather than derived directly from embryos, the mutational load differences may 168 
not be intrinsic to different cell states, but may in fact reflect a substantial selection pressure imposed 169 
on the cells during resetting to naïve pluripotency.  Supporting the latter view, the genes found to 170 
be mutated in the naïve cells  were in pathways affected by chemical inhibitors used in resetting 171 
primed cells to the naïve state(Avior et al., 2019). 172 
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The studies by Merkle et al (2017) and Avior et al (2019) offered an important insight into the 173 
mutational landscape of PSC, albeit they focused on analysing a relatively small portion of the 174 
PSC genome (i.e. the exome, which represents only about 1% of the genome).  Undoubtedly, 175 
uncovering the true extent and pattern of point mutations arising in PSC will require much larger, 176 
ideally longitudinal datasets, and scrutiny of PSC sequence changes at a genome-wide level. 177 
Important for this endeavour will be the implementation of next generation sequencing as a 178 
component of routine monitoring of PSC genomes. Currently, the turnaround time and cost of 179 
sequencing preclude its use as a routine screening method, but the ongoing technological 180 
developments, which are driving down the cost and the data processing time, make this a feasible 181 
prospect for the coming decade. Nonetheless, we must remain cognizant of the fact that the 182 
reliable detection of mutations is only the first step in handling culture-acquired genetic changes. 183 
A far more difficult hurdle is ascribing the functional meaning to the detected mutations, and 184 
predicting their potential impact for applications of human PSC. 185 
 186 
Consequences for applications of human PSC 187 
The close relationship between experimentally-derived PSC and EC cells, the malignant stem cells 188 
of teratocarcinomas, which occur predominantly as testicular germ cell tumors in young men 189 
(Andrews, 2002, Mostofi and Price, 1973, Damjanov and Solter, 1974), and the ability of PSC to 190 
produce teratomas when grown in immunodeficient mice, has always provoked concerns that cancer 191 
presents a significant safety hazard for PSC based regenerative medicine.  However, it is important 192 
to recognize the distinction between teratomas and teratocarcinomas.  Teratomas are tumors 193 
containing differentiated cells without any persisting PSC.  By contrast, teratocarcinomas are tumors 194 
with the characteristics of teratomas that also contain undifferentiated PSC (Figure 2) (Damjanov 195 
and Andrews, 2007b, Damjanov and Andrews, 2016).  Clinically, teratocarcinomas are highly 196 
malignant cancers, but they can also be effectively treated because PSC are exceptionally sensitive 197 
to the chemotherapeutic agent, Cis-Platinum (Einhorn and Donohue, 1977, Oosterhuis et al., 1984, 198 
Einhorn et al., 1981) as part of a standard treatment that also includes Bleomycin and Etoposide 199 
(Williams et al 1987).  Although some PSC do produce teratocarcinomas in which undifferentiated 200 
PSC can be recognized histologically, or by outgrowths of PSC from explanted tumors (Andrews et 201 
al., 2005), many of the xenograft tumors derived from PSC are better classified as teratomas (Allison 202 
et al., 2018).  It might be anticipated that variant PSC carrying mutations that enhance their 203 
proliferative potential and, perhaps, reduce their propensity to differentiate would be more likely to 204 
generate teratocarcinomas.  Certainly, aneuploid PSC can produce teratocarcinomas (Andrews et 205 
al., 2005).  Further, the transcriptomes of ESC carrying an extra copy of chromosome 12 clustered 206 
more closely with EC cells from germ cell tumors, which almost always exhibit a gain of the short 207 
arm of chromosome 12, while ESC with a gain of chromosome 12 were more likely to produce 208 
teratocarcinomas than the parent diploid cells from which they were derived (Ben-David et al., 2014).  209 
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On the other hand, in a recent ISCI study, albeit limited in scope, teratocarcinomas were produced 210 
by PSC without overt karyotypic abnormalities, whereas PSC with such variants, including gains of 211 
chromosome 12, produced teratomas, indicating no clear correlation between the formation of 212 
teratocarcinomas and the presence of overt karyotypic changes (Allison et al., 2018).  These 213 
discrepancies point to the need for a more systematic study of the relationship between genotype 214 
and the ability of PSC to form teratocarcinomas rather than teratomas. 215 
On the other hand, regenerative medicine applications depend upon transplantation of specific 216 
differentiated derivatives, not undifferentiated cells, so it is the possibility that genetic variants of PSC 217 
may cause a neoplastic transformation of their derivative differentiated cells that is the greater 218 
concern (Figure 2).  Unfortunately, there is very little direct evidence upon which to draw any definite 219 
conclusions about the extent of the risks.  The somatic elements in teratomas of the laboratory 220 
mouse are almost always benign and non-tumorigenic (Damjanov and Solter, 1974) and this may 221 
be generally true of human teratomas.  However, pathologists with expertise in clinical gonadal 222 
teratocarcinomas do have concerns since in the human tumors, in contrast to those of the laboratory 223 
mouse, many of the differentiated elements such as neural tubes exhibit features of immaturity that 224 
may be regarded as potentially neoplastic (Damjanov and Andrews, 2016).  Certainly, secondary 225 
somatic tumors derived from primary germ cell tumors have been found clinically, although they are 226 
very rare (Mostofi and Price, 1973).  Experimental, PSC-derived teratomas often also contain 227 
primitive endodermal elements, which is a further concern since yolk sac carcinoma, representing 228 
malignant primitive endoderm, is a well-known clinical form of germ cell tumors of the newborn 229 
(Cunningham et al., 2012). 230 
Although the relationship of malignant transformation of teratoma elements to particular genetic 231 
variants has not been established, some of the common karyotypic variants occurring in human PSC 232 
are also associated with other types of somatic cancer - for example, gains of the long arm of 233 
chromosome 17 with neuroblastoma (Plantaz et al., 1997) (BOX 2).  Further, two of the genes 234 
associated with recurrent variants in human PSC, TP53 (Merkle et al., 2017) and BCL2L1, the driver 235 
gene of the chromosome 20q amplicon (see below) (Avery et al., 2013), which derive their selective 236 
advantage for PSC from their anti-apoptotic functions, are associated with many cancers (Beroukhim 237 
et al., 2010, Hainaut and Hollstein, 1999).  Although the driver genes of the other common recurrent 238 
variants of human PSC have yet to be identified, they provide a selective advantage because of their 239 
specific effects on the undifferentiated PSC and it is entirely possible that their effects on specific 240 
differentiated derivatives may be quite different.  However, since many of the recurrent variants 241 
involve gains or losses of large chromosomal regions, it is also possible that other ‘hitch-hiker’ genes 242 
linked to the driver gene may also cause effects in the differentiated derivatives, separately from the 243 
effects of the driver genes on the undifferentiated PSC themselves. 244 
Apart from cancer, the genetic variants of PSC have the potential to cause a wide range of effects 245 
on cellular physiology that could compromise the efficacy of derivative cells used in clinical 246 
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applications, or the production of such cells, or indeed the use of PSC in research, for example into 247 
disease mechanisms.  Nevertheless, there has been very little systematic consideration of these 248 
issues.  They were discussed by international key opinion leaders at a meeting of the International 249 
Stem Cell Initiative (ISCI), at the Jackson Laboratory in 2016 (Andrews et al., 2017), and again at a 250 
meeting hosted by Nature in London in 2018 (Technologies, 2018), while the Japanese regulatory 251 
authorities have issued some guidelines (Research and Development Division, Health Policy 252 
Bureau, The Ministry of Health, Labour and Welfare (MHLW), 253 
http://www.nihs.go.jp/cbtp/sispsc/pdf/Eg.ver.Annex_0613-3_2016.pdf).  However, there is no 254 
international consensus about potential risk assessment and the ISCI meeting in 2016 suggested 255 
the establishment of an advisory group to collate information about the common genetic variants of 256 
PSC, including any evidence of their effects on cell behaviour, and linking that information to other 257 
cancer and disease related genomic databases.  Meanwhile, the Nature meeting strongly 258 
recommended that researchers clearly document any genetic variants that may have been present 259 
in cells used for particular research, so providing the data for future retrospective analysis of their 260 
potential consequences.  Certainly, as a minimum, the documentation should include appropriate 261 
characterisation of the karyotype of the cells, and also assessment of the chromosome 20 amplicon, 262 
given that these represent the most commonly observed genomic changes seen in these cells. 263 
 264 
SELECTION DRIVES THE APPEARANCE OF RECURRENT GENETIC VARIANTS  265 
Growth advantage  266 
Although genetic variants may be occasionally fixed when PSC cultures are passed through a 267 
population bottleneck, such as cloning, the recurrence of specific mutations within PSC populations 268 
suggests that such genetic changes endow the variant cells with a selective growth advantage.  269 
Consistent with this, the proportions of variant cells in a culture typically increase over time from 270 
when they are first detected (Draper et al., 2004, Catalina et al., 2008, Imreh et al., 2006).  Similarly, 271 
in experiments designed to recapitulate the takeover of cultures by variant clones, co-mixing a small 272 
proportion of commonly occurring variants with their wild-type counterparts led to a gradually 273 
increased representation of variant cells in subsequent passages until they eventually dominated 274 
the cultures (Olariu et al., 2010, Avery et al., 2013).  Commonly, a variant may be first detected when 275 
it constitutes around 5 – 10% of the cells in a culture, rising rapidly to 100% in as few as 5 passages.  276 
Based on these longitudinal evaluations, the takeover of PSC cultures by variant cells has been 277 
likened to Darwin’s principle of natural selection, whereby the variant PSC that are best adapted to 278 
particular selective conditions outcompete their neighbours and populate cultures with their own 279 
progeny.  The specific phenotypic features associated with genetic variants hold clues as to the 280 
selective pressures operating in PSC cultures, the reduction of which is key to minimising the 281 
appearance of genetic variants in expanding PSC populations. 282 
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In principle, genetically variant PSC could gain a selective advantage by acquiring one or several of 283 
the following features: a proliferative advantage underpinned by faster cell cycle time, a decreased 284 
rate of differentiation, or altered pattern of differentiation, or an increased rate of survival (Figure 3).  285 
Indeed, a number of studies have reported that such traits typify variant cells harbouring the 286 
commonly acquired aneuploidies.  For example, the growth advantage of trisomy 12 PSC was 287 
attributed mainly to their significantly reduced cell cycle time, although the variant cells also displayed 288 
an increased resistance to apoptosis and a reduced tendency for differentiation (Ben-David et al., 289 
2014).   290 
With regard to the reduced propensity for differentiation, no studies have so far reported a total block 291 
of variant ESC or iPSC to differentiation, although nullipotent EC cells are well known in the context 292 
of testicular germ cell tumors (Andrews et al., 1980, Andrews et al., 1982).  Rather, either a reduced 293 
differentiation capacity (Fazeli et al., 2011) or a delayed differentiation dynamic (Werbowetski-294 
Ogilvie et al., 2009) compared with wild-type cells has been observed.  In some instances, 295 
genetically variant PSC appeared to yield alternative cell types to wild-type cells exposed to the 296 
same set of differentiation conditions.  For example, the same differentiation protocol applied to wild-297 
type PSC and variants with a gain of the long arm of chromosome 17 resulted in mesodiencephalic 298 
dopaminergic neurons or dorsal telencephalic neurons, respectively (Lee et al., 2015).  Given that 299 
this gain entails amplification of a large chromosomal region and, hence, increased expression of 300 
most of the genes in that region (Enver et al., 2005), it is easy to envision that such extensively 301 
altered gene and protein expression profiles could include changes that skew the differentiation 302 
trajectory of cells.  In this case, the skewed differentiation was attributed to an increased expression 303 
of WNT3 and WNT9B genes localized in the amplified part of chromosome 17 (Lee et al., 2015).  In 304 
another case, it has been reported that BCL-XL over expression perturbs SMAD and TGFβ signalling 305 
in PSC with the chromosome 20q11.21 gain, resulting in impaired neurectoderm differentiation 306 
(Markouli et al., 2019).  Although the altered propensity for differentiation of variant cells may be a 307 
mere consequence of hitch-hiker genes rather than the driver of their growth advantage, the 308 
converse may also hold true if the differentiation process itself exerts selection on the differentiating 309 
cells.  For example, in one study, cardiac differentiation favoured cells with a gain of the long arm of 310 
chromosome 20 (Laurent et al., 2011) whereas in another report Merkle et al (Merkle et al., 2017) 311 
noted an enrichment of mutant TP53 cells upon PSC differentiation.  In both cases, a variant PSC 312 
population was already present in the starting cultures prior to differentiation, but it is also possible 313 
that variant cells may arise and be selected during the differentiation process itself. 314 
Although faster cell cycle and altered differentiation have been associated with some of the recurrent 315 
variants, resistance to apoptosis seems to be a frequent feature of variants commonly detected in 316 
PSC cultures.  This is, perhaps, not surprising given that marked sensitivity to apoptosis represents 317 
one of the notable features of early-passage diploid PSC.  Excessive cell death is particularly 318 
prominent when PSC are grown at a low cell density (Ohgushi et al., 2010), a condition under which 319 
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single PSC are confronted with a series of bottlenecks preventing their clonal growth (Barbaric et al., 320 
2014).  At the molecular level, propensity for apoptosis has been explained by a low apoptotic 321 
threshold of PSC, governed by low expression levels of anti-apoptotic proteins and high expression 322 
levels of pro-apoptotic proteins (Liu et al., 2013).  In addition to preferential expression of pro-323 
apoptotic factors, PSC store a constitutively active pro-apoptotic factor BAX in the Golgi (Dumitru et 324 
al., 2012).  This effectively primes PSC for a rapid apoptotic response to appropriate cues.  Apart 325 
from hampering the efficient scale up of PSC, the severe reduction in cell numbers during culture 326 
clearly creates conditions for selection of genetically variant cells capable of blunting the apoptotic 327 
pathways (Avery et al., 2013, Merkle et al., 2017). 328 
The emergence of variant cells in PSC cultures inevitably entails interactions of variants with their 329 
wild-type counterparts, as the two populations share their environment and some of their cell-cell 330 
contacts.  The nature of these interactions can determine the fate of wild-type cells in a non-cell 331 
autonomous manner, thereby impacting on the dynamics of the variant’s overtake of cultures (Figure 332 
3).  Some of the commonly occurring PSC variants were shown to suppress the growth of wild-type 333 
populations by inducing apoptosis in their neighbouring wild-type cells (Price et al., 2019), in a 334 
manner similar to the phenomenon of cell competition described in other model systems (Bowling et 335 
al., 2019).  In PSC cultures, a differential sensitivity of wild-type and variant PSC to mechanical 336 
pressures imposed by cell crowding allowed variants to effectively eliminate wild-type cells from 337 
mixed cultures, therefore enhancing the ability of variants to rapidly achieve the clonal dominance 338 
(Price et al., 2019). Therefore, consideration of cell interactions, in addition to cell autonomous 339 
mechanisms, is needed in developing effective strategies for prevention of growth supremacy of 340 
variant cells.  341 
 342 
Driver genes 343 
The simplest working hypothesis to account for the recurrent selection of a particular chromosomal 344 
variant is that it is the altered expression of a single ‘driver’ gene located in the variant region that 345 
provides a growth advantage by altering a cell’s behaviour in response to proliferation, differentiation 346 
or cell death cues (Figure 3).  It is, of course, possible that interaction of multiple linked genes in a 347 
particular chromosomal rearrangement, or indeed alterations to the chromatin architecture itself, 348 
may be responsible.  Nevertheless, most studies have focused on seeking a single driver gene. 349 
Often the size of the genomic region affected is too large to home in on a likely candidate, but in the 350 
case of amplifications affecting chromosome 20, a common minimal amplicon of 0.55Mb was 351 
identified in the pericentromeric region of the long arm in all reported examples (Amps et al., 2011).  352 
Within this minimal amplicon, containing only thirteen annotated genes, BCL2L1 was a likely 353 
candidate driver gene as its anti-apoptotic splice variant, BCL-XL, is expressed in human PSC (Amps 354 
et al., 2011).  Experiments in which cells carrying a gain chromosome 20, or that had been 355 
transfected with a BCL2L1-over expressing vector, were mixed with diploid cells, confirmed that 356 
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BCL2L1 and its BCL-XL product was indeed the driver providing a selective growth advantage by 357 
blocking apoptosis (Nguyen et al., 2013, Avery et al., 2013). 358 
Like chromosome 20, a common minimal amplicon has also been identified on the long arm of 359 
chromosome 1 (Baker et al., 2016)(E.  McIntire et al, International Society for Stem Cell Research 360 
Meeting abstract).  A likely candidate driver gene located in this region is MDM4, which regulates 361 
p53 by suppressing its response to cellular stresses and increasing the threshold to apoptosis (Haupt 362 
et al., 2019).  Since recurrent dominant negative mutations of TP53 provide a growth advantage to 363 
human PSC (Merkle et al., 2017) it is likely that dysregulation of other genes, such as MDM4, that 364 
affect apoptosis through p53 would confer a similar growth advantage.  On the long arm of 365 
chromosome 17, another anti-apoptotic gene, SURVIVIN (BIRC5), encoded in the chromosome 366 
17q25.3 region, has been proposed since its inhibition leads to apoptosis of human PSC and cancer 367 
cells (Blum et al., 2009, Mesri et al., 2001, Ma et al., 2006, Yang et al., 2004).  On the other hand, 368 
other candidate genes encoded on chromosome 17 include WNT3 and WNT9B, suggested by their 369 
involvement in the altered patterns of differentiation of cells carrying a gain of the long arm of 370 
chromosome 17 (Lee et al., 2015). 371 
Interest in gains of chromosome 12 has a long history since testicular germ cell tumors almost always 372 
have a gain of the short arm, mostly as an isochromosome (Atkin and Baker, 1982), or more rarely 373 
as an interstitial amplification (Rodriguez et al., 2003, Korkola et al., 2006).  However, there is no 374 
definitive evidence to identify the specific driver gene, either for the progression of germ cell tumors, 375 
or for the appearance of variant human PSC with a gain of chromosome 12.  An obvious candidate 376 
driver gene on the short arm of chromosome 12 is NANOG, given its central role in maintaining 377 
pluripotency, and that its over-expression inhibits differentiation (Chambers et al., 2007).  Also, over 378 
expression of NANOG does allow human ESC to efficiently form colonies at low density, which is 379 
normally associated with extensive apoptosis, perhaps mediated by downregulating LECTIN1, which 380 
normally promotes apoptosis, and upregulating HSPA1A, which inhibits apoptosis (Darr et al., 2006).  381 
Indeed, NANOG is located in a minimal amplicon that has been identified in germ cell tumors, 382 
chromosome 12p13.31, but so are two other genes, DPPA3 and GDF3, that also may affect the 383 
behaviour of human PSC (Korkola et al., 2006).  However, a different minimal amplicon has also 384 
been reported in human germ cell tumors, at 12p11.2–p12.1, in which a number of other genes have 385 
been highlighted, such as the oncogene, KRAS (Rodriguez et al., 2003). 386 
Although less frequent, deletions may promote enhanced survival through copy number loss of pro-387 
apoptotic genes.  The BCL-2 apoptotic pathway is controlled by interactions between pro- and anti-388 
apoptotic protein family members.  Human ESC show elevated expression of the pro-apoptotic 389 
genes NOXA, BIK, BIM, BMF and PUMA, which may contribute to their low apoptotic threshold 390 
(Madden et al., 2011, Liu et al., 2013, Dumitru et al., 2012).  The two of these most highly expressed 391 
in human PSC, NOXA and BIK, are located in chromosomal regions, 18q21.32 and 22q13.2, that do 392 
undergo recurrent deletion.  Deletion of NOXA by genetic manipulation decreases the sensitivity of 393 
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human PSC to mitotic errors, thereby increasing the survival of aneuploidy cells (Zhang et al., 2019), 394 
and improves survival during cell dissociation, similar to the overexpression of the anti-apoptotic 395 
proteins, BCL-2 and BCL-XL (Ohgushi et al., 2010, Ardehali et al., 2011). 396 
 397 
ACQUISITION OF MUTATIONS 398 
Mutation Rate in PSC 399 
Whereas the mechanisms by which genetic variants offer cells a selective growth advantage are 400 
relatively easy to assess and have been extensively studied, addressing the mechanisms that drive 401 
the appearance of the variants in the first instance is more problematic:  Mutations occur 402 
stochastically and at low frequency in single cells within much larger populations, so that by the time 403 
they become detectable the frequency of mutation may have been grossly distorted by the effects of 404 
selection.  To overcome this problem, we recently adopted a clonogenic strategy in which a single 405 
cell was isolated and allowed to expand as a clonal colony for a fixed time, after which the clone was 406 
subcloned, with about 20 subclones being isolated and, after expansion, subjected to whole genome 407 
sequencing (Thompson et al., 2020).  Using this approach, in which most of the mutants that arose 408 
were in genes and locations unlikely to result in growth advantage or disadvantage, we estimated 409 
the mutation rate of two human, clinical grade ESC lines, MShef4 and MShef11, as 0.37 x10-9 and 410 
0.28x10-9 SNVs per base pair, per day, respectively, equating to approximately 0.30 x10-9 and 411 
0.23x10-9 SNVs per cell division, respectively, given that the cell cycle time of human PSC, in our 412 
experience, approximates 20 hours (+/- 2 hours) (Barbaric et al., 2014).  This rate was not affected 413 
by the use of the Rho associated coiled coil containing protein kinase (ROCK) inhibitor, Y-27632, 414 
commonly used in human PSC culture (Watanabe et al., 2007)  The frequency of INDELS was 10-415 
fold lower.  These low rates are comparable with another study of human iPSC in which the mutation 416 
rate was estimated to be 0.18 x 10-9 SNV per base-pair, per cell division which was considerably 417 
lower than in the endothelial progenitor cells (Rouhani et al., 2016).  These mutation rates in human 418 
PSC contrast with an estimated rate of 2.66 x 10-9 mutations per base pair, per mitosis in somatic 419 
cells (Milholland et al., 2017).  In another more limited study of a human ESC line, a slightly higher 420 
mutation rate of 1 x 10-9 SNV per base-pair, per cell division, but again this was much lower than an 421 
estimate of a corresponding somatic cell in the same study (Kuijk et al., 2018), while in a study of a 422 
single locus, Aprt, in mouse ESC, the mutation rate was estimated to be 10 fold lower than in 423 
corresponding somatic cells (Cervantes et al., 2002).  These low rates are consistent with the 424 
infrequency of recurrent point mutations observed in PSC lines: for example Merkle et al (2017) 425 
(Merkle et al., 2017) only observed mutations in TP53 in five out of 140 human PSC lines. 426 
In our study of the MShef4 and MShef11 human ESC lines (Thompson et al., 2020), the mutation 427 
rate was similar across all chromosomes, with no obvious hotspots, with the exception of a slightly 428 
raised rate on the X chromosome, which might have been a consequence of both lines being male.  429 
Nevertheless, the mutation rate was significantly higher in intergenic regions than in exons and 430 
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introns, suggesting an influence of chromatin structure on mutation.  Further, the predominant 431 
mutation signatures that we detected were consistent with oxidative damage being the predominant 432 
cause of mutation and, indeed, the mutation rate for both SNV and INDELS was reduced by about 433 
50% when the cells were maintained under low (5%) oxygen atmospheres. 434 
 435 
DNA Replication Stress and Mitotic Errors 436 
While many SNV in PSC, as in other cultured cells (Petljak et al., 2019, Kucab et al., 2019, Viel et 437 
al., 2017), are caused by misincorporation of bases due to oxidative stress, the relatively rapid cell 438 
cycle of PSC might also expose them to high levels of DNA replication stress, characterised by 439 
reduced rates of DNA replication together with stalling and collapse of replication forks (Bartkova et 440 
al., 2005, Gorgoulis et al., 2005).  Errors in the repair of resulting double stranded DNA breaks could 441 
then lead to chromosomal rearrangements (Cannan and Pederson, 2016).  Self-renewal of human 442 
PSC is characterised by an abbreviated G1 phase that bypasses the RB1-E2F checkpoint due to 443 
the high expression of cyclin D2 and its CDK4 partner together with the constitutive expression of 444 
cyclin E, which together maintain RB1 in a hyperphosphorylated and inactive state (Becker et al., 445 
2006, Becker et al., 2010, Filipczyk et al., 2007).  Using DNA fibre assays we have recently found 446 
that, in comparison to isogenic somatic cells, human PSC do exhibit the features of DNA replication 447 
stress, including slower DNA replication speeds with evidence of stalled replication forks, and 448 
replication initiating from quiescent replication origins (Figure 4) (Halliwell et al., 2019).  In parallel 449 
we also observed more extensive replication-associated DNA damage in the PSC compared to 450 
somatic cells, as has also been reported by others (Simara et al., 2017, Vallabhaneni et al., 2018).   451 
A similar situation pertains in many cancers where cyclin E is frequently over-expressed and RB1-452 
E2F is constitutively activated (Akli and Keyomarsi, 2003).  One of the consequences of this is 453 
replication stress, double stranded breaks and genetic instability (Bester et al., 2011, Burrell et al., 454 
2013, Frame et al., 2006, Pickering and Kowalik, 2006).  In mouse ESC, also, molecular hallmarks 455 
of replication stress are almost identical to those observed when oncogenes, such as cyclin E, are 456 
dysregulated in somatic cells (Ahuja et al., 2016), suggesting that atypical cell cycle control with 457 
consequent susceptibility to DNA replication stress and genomic damage in PSC parallels the 458 
oncogene-induced DNA damage model for cancer development and progression (Halazonetis et al., 459 
2008). 460 
Replication stress induced from oncogene expression can lead to nucleotide deficiency and collision 461 
of replication forks with transcription complexes (Jones et al., 2013, Bester et al., 2011).  462 
Supplementing cancer cells or primary cell lines that overexpress oncogenes, such as cyclin E, with 463 
nucleosides has been found to alleviate replication stress and its associated DNA damage and 464 
genetic instability in these cases (Bester et al., 2011, Burrell et al., 2013).  In a similar manner, we 465 
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have recently found that exogenous nucleosides increase the rate of replication fork progression and 466 
decrease DNA damage in human PSC cultures (Figure 4) (Halliwell et al., 2019). 467 
While chromosomal non-dysjunction and numerical instabilities may be the product of merotelic 468 
kinetochore attachment, in which the microtubules from both poles bind to the same sister chromatid, 469 
leading to lagging and potential mis-segregation of chromosomes (Cimini et al., 2001), the 470 
persistence of DNA replication defects from S phase into mitosis can also result in the formation of 471 
mitotic errors that are a source of chromosomal instabilities (Burrell et al., 2013).  Under-replicated 472 
regions can interlink sister chromatids during segregation forming anaphase bridges that are prone 473 
to breakage forming double stranded breaks (Chan et al., 2009).  Often, to prevent anaphase 474 
bridges, nucleases cleave the DNA that again generates double stranded breaks (Naim et al., 2013).  475 
Further, the condensation of chromosomes that harbour replication intermediates are particularly 476 
prone to breakage (Lukas et al., 2011).  These double stranded breaks that result from replication 477 
intermediates in mitosis are the substrates for genetic instability caused by error induced repair.   478 
By fluorescently labelling human PSC with histone H2B-mCherry it was observed that 30% of 479 
mitoses were abnormal including a high proportion with lagging chromosomes and anaphase bridges 480 
(Zhang et al., 2019), a level substantially higher than that observed in somatic cell lines (Lamm et 481 
al., 2016).  In comparison to somatic cell lines, diploid human PSC show condensation defects that 482 
result in partially condensed and entangled chromosomes (Lamm et al., 2016).  Supplementing 483 
cultures with exogenous nucleosides alleviated replication stress and decreased the frequency of 484 
mitotic errors, providing further evidence that these are linked in human PSC (Halliwell et al., 2019), 485 
as well as providing an approach to reducing their appearance in PSC cultures.  However, it should 486 
be noted that the continued occurrence of mitotic errors, even with the addition of nucleosides 487 
suggests that there are other factors driving their occurrence. 488 
 489 
Response to genomic damage 490 
Human PSC deploy a number of mechanisms to minimise the effective mutation rate that otherwise 491 
might be anticipated from their high susceptibility to DNA damage.  Genes involved in various repair 492 
pathways show increased expression compared to somatic cells (Maynard et al., 2008, Momcilović 493 
et al., 2009), and nucleotide excision repair, base excision repair, and the resolution of inter-strand 494 
crosslinks caused by ionising radiation all have all been reported to be faster in human PSC than 495 
somatic cell lines (Luo et al., 2012, Hyka-Nouspikel et al., 2012, Maynard et al., 2008).  PSC also 496 
tend to repair double strand break using homologous recombination, which is prone to less errors 497 
than non-homologous end joining (Adams et al., 2010a), although they do also utilise a higher fidelity 498 
system of non-homologous end joining that is independent of DNA-PKc and ATM (Adams et al., 499 
2010b).  Further, in response to the formation of reactive oxygen species as a by-product of 500 
respiration, and consequent oxidative stress, PSC express higher levels of SOD2 and GPX2 anti-501 
oxidant enzymes compared to differentiated lines (Saretzki et al., 2008). 502 
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Nevertheless, human PSC generally activate apoptosis when exposed to lower doses of genotoxic 503 
insults than do somatic cells, suggesting that a low apoptotic threshold is the key element in their 504 
response to genomic damage.  After human PSC are exposed to ultraviolet C radiation to induce 505 
nucleotide base adducts or DNA breaks they respond with extensive apoptosis even at mild doses 506 
that have little effect on somatic cell lines (Hyka-Nouspikel et al., 2012, Luo et al., 2012, Simara et 507 
al., 2017).  Similarly, the treatment of human PSC with cis-platinum or thymidine to initiate replication 508 
block (Desmarais et al., 2012, Desmarais et al., 2016), or with nocadazole to induce mitotic block 509 
(Zhang et al., 2019) also elicits an extensive apoptotic response in contrast to the response by 510 
somatic cells, while PSC also efficiently activate apoptosis in response to oxidative stress (Saretzki 511 
et al., 2008).  The particular sensitivity of embryonal carcinoma cells, the malignant PSC of 512 
teratocarcinomas, to drugs such as cis-platinum (Oosterhuis et al., 1984, Einhorn and Donohue, 513 
1977), a DNA cross linking agent, makes germ cell tumors one of the most treatable forms of solid 514 
cancer, most likely reflecting this particular low apoptotic threshold. 515 
An atypical cell cycle checkpoint control mechanism most likely underlies the low apoptotic threshold 516 
of human PSC.  In response to DNA damage, human PSC fail to activate p21, which is normally 517 
required to execute the G1/S checkpoint, providing less time for repair before apoptosis is initiated 518 
in a p53 dependant manner (Hyka-Nouspikel et al., 2012, Hong and Stambrook, 2004, Momcilović 519 
et al., 2009).  Further, in response to DNA replication stress caused by high levels of thymidine, or 520 
the presence of cis-platinum, human PSC, unlike somatic cells, do not activate ATR-CHK1, while 521 
foci of RPA, which binds to single stranded DNA at stalled replication forks, are not formed: instead 522 
the cells commit to apoptosis (Desmarais et al., 2012, Desmarais et al., 2016).  Human PSC also 523 
undergo extensive apoptosis in response to mitotic stress which may safeguard the genome from 524 
abnormal mitosis by clearing the effected cell from the cell pool (Zhang et al., 2019).  Collectively, 525 
these studies support a model in which genomic stability, and the particularly low observed mutation 526 
rate of PSC is primarily maintained by a low apoptotic threshold.  Consequently, blocking apoptosis 527 
seems to be the most likely mechanism that provides selective growth advantage for the common 528 
genetic variants found in human PSC: the two driver genes so far identified, TP53 and BCL2L1, both 529 
act to inhibit apoptosis, while other proposed candidates, MDM4 and SURVIVIN, are also anti-530 
apoptotic.   531 
This low apoptotic threshold of human PSC may reflect their relationship to the early embryo in which 532 
the need for rapid cell doublings is accomplished by the lack of cell cycle checkpoints, rendering the 533 
cells particularly susceptible to errors in DNA synthesis and mitosis, which could be catastrophic for 534 
subsequent embryonic development.  Indeed, almost half of human embryos fail to survive due to 535 
chromosomal instability, which does not seem to be a mere artefact of in vitro fertilisation (van 536 
Echten-Arends et al., 2011, Munné et al., 2019, Starostik et al., 2020).  It has been observed that 537 
the mosaic embryos that survive to the blastocyst stage undergo “genetic normalization” when 538 
cultured under routine IVF conditions (Brezina et al., 2011).  The mechanism of genetic normalization 539 
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is still widely debated although, in the mouse, activation of apoptosis during the later pre-implantation 540 
stages may allow for the removal of aneuploid cells from the developing embryo (Kops et al., 2004, 541 
Bolton et al., 2016).  This model is supported by observations that the proportion of aneuploidy in 542 
the inner cell mass is reduced, whereas in the trophectoderm it is enriched as development proceeds 543 
(Hardy, 1997).  However, this is still widely debated as apoptosis is a feature of all embryos, and 544 
may be a mechanism for maintaining cellular homeostasis regardless of their genomic state (Haouzi 545 
and Hamamah, 2009). 546 
Another context in which the apoptotic response of human PSC to DSB induction is of central 547 
importance, is the process of genome editing.  The rising prominence of genome editing 548 
technologies, in particular CRISPR/Cas9-based methods, has fuelled efforts aimed at, for example, 549 
correcting germline mutations in PSC to allow autologous cell therapy, or removing HLA antigens to 550 
reduce the need for immunosuppressants in transplanted patients.  Crucially, as gene editing relies 551 
on the induction of DSB by nucleases, the edited PSC undergo high levels of apoptosis in 552 
comparison to their unedited counterparts (Ihry et al., 2018).  The rate of cell death was shown to be 553 
similar between different, edited PSC, regardless of whether the targeted gene was expressed in 554 
PSC or whether it was non-expressed and dispensable for PSC maintenance.  This observation 555 
supports the view that the induction of DSB during the gene editing process commits PSC to 556 
apoptosis (Ihry et al., 2018).  Mechanistically, DSB induction by Cas9 was shown to trigger 557 
differential gene expression in edited cells, most notably by promoting the TP53 transcriptional 558 
response (Ihry et al., 2018).  In line with the importance of TP53 activation during the genome editing 559 
process, performing the PSC genome editing in cells with genetically inactivated TP53 reduced the 560 
levels of cell death and improved the efficiency of PSC genome editing (Ihry et al., 2018).  While 561 
genetic inactivation of TP53 is deemed too risky for editing of cells destined for clinical use, transient 562 
TP53 inactivation has been proposed as a possible alternative (Schiroli et al., 2019). Further work 563 
will need to carefully address this possibility, to ensure that the transient TP53 inactivation does not 564 
inadvertently select for TP53 genetic mutants.  Relevant to this notion is the recent data 565 
demonstrating the emergence of TP53-inactivating mutations in cancer cell lines during the 566 
CRISPR/Cas9 genome editing process (Enache et al., 2020). 567 
 568 
CONCLUSIONS 569 
Efforts to collect and catalogue genetic variation in PSC over the last two decades demonstrated 570 
that particular variants do arise in cultures and are sometimes difficult to detect because of the 571 
limitation of sensitivity of detection methods.  Nonetheless, it is reassuring that the rate of mutation 572 
in PSC cultures is low compared with somatic cells.  Indeed, based on the data from large-scale 573 
retrospective studies, such as the ISCI (Amps et al., 2011), and on the direct measurements of the 574 
mutation rates in PSC (Thompson et al., 2020), there is no evidence to suggest that PSC genomes 575 
are particularly unstable.  Rather, the clonal expansion of genetic variants against the backdrop of 576 
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low mutation rates, can be explained by the effect of selective pressures operating in PSC cultures.  577 
Optimizing culture conditions and protocols to minimize the growth advantages of the common 578 
variants is, therefore, a key route to maintaining the genetic integrity of PSC lines.  However, the 579 
predominant selective force dominating PSC cultures appears to be a high rate of apoptosis (Dumitru 580 
et al., 2012, Barbaric et al., 2014).  Apoptosis seems to be a default fate choice of PSC in many 581 
different scenarios, including a response of cells to genome damage or mitotic stress (Desmarais et 582 
al., 2012, Desmarais et al., 2016, Dumitru et al., 2012, Zhang et al., 2019), most likely reflecting its 583 
function of maintaining the genetic integrity of the early embryo.  Consequently, optimising culture 584 
conditions should entail removing the apoptotic stimuli, but not blocking apoptosis per se which 585 
would be counterproductive.   586 
Armed with a knowledge of recurrent karyotypic and sequence changes, our attention now needs to 587 
turn to finding ways of minimizing their occurrence by lowering the genome damage and reducing 588 
the selective pressures.  In that respect, the observations that mutation rates can be decreased by 589 
growing cells under low oxygen (Thompson et al., 2020) and that replication-stress induced genome 590 
damage can be alleviated by addition of exogenous nucleosides (Halliwell et al., 2019) provide 591 
foundations for optimised culture conditions of PSC.  Further work should also address the 592 
contribution of epigenetic variants to aberrant PSC phenotypes, as the understanding of epigenetic 593 
variation in PSC cultures remains limited. 594 
Finally, the field awaits deciphering of the functional consequences of the karyotype and sequence 595 
changes on PSC traits and on the behaviour of their differentiated derivatives.  Interpreting the role 596 
of specific variants is complicated by the fact that their consequences are likely to be context-597 
dependent.  For example, a mutation in a gene expressed specifically in an endodermal lineage may 598 
have little impact on the clinical application of neuronal cells.  To aid these analyses, ISCI is 599 
proposing an international study group to collate and monitor evidence of genetic variants in PSC 600 
and their potential consequences (Andrews et al., 2017).  However, it should be noted that the 601 
success of this approach requires a concerted effort within the field to perform routine monitoring 602 
and report the presence of genetic variants, thereby allowing retrospective analyses of their effects.  603 
We envisage that these initiatives, in a synergy with cancer genome efforts, would provide a rational 604 
strategy to assess the potential risk of different mutations, a necessary requirement for routine, safe 605 
clinical implementation of cellular therapies. 606 
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FIGURE LEGENDS 1056 
 1057 
Figure 1:  Appearance of mutations in human PSC involves both mutation and 1058 
selection. 1059 
Human PSC are subject to the full range of mutations seen in other systems, including single 1060 
base changes and small insertions and deletions (INDELS) (Thompson et al., 2020), as well 1061 
as larger scale genomic rearrangements with gains or losses of whole chromosomes or 1062 
chromosomal fragments that alter the number of copies of whole sets of genes, and 1063 
consequently their levels of expression (Enver et al., 2005).  The most commonly seen 1064 
chromosomal rearrangements are illustrated.  Generally, in the absence of a clonogenic 1065 
bottleneck, these mutations will never be detected unless they offer the mutant cell a 1066 
selective growth advantage (Olariu et al., 2010). 1067 
 1068 
Figure 2:  Nature of tumors derived from pluripotent stem cells 1069 
PSC produce tumours that may contain both undifferentiated PSC together with their 1070 
differentiated derivatives, in which case the tumor is termed a ‘Teratocarcinoma’ and is 1071 
regarded as highly malignant.  If the PSC fully differentiate, so that the tumor contains only 1072 
differentiated derivatives, it is termed a ‘Teratoma’ and is generally regarded as benign and 1073 
not malignant (Damjanov and Andrews, 2007a, Damjanov and Andrews, 2016).  However, 1074 
a caveat is that some of the differentiated derivatives may develop into a secondary 1075 
malignancy corresponding to their particular cell type, and this may be driven by a mutation 1076 
present in the parent PSC.  In addition to somatic derivatives, PSC may also generate 1077 
primitive endoderm elements which are precursors of highly malignant yolk sac carcinomas 1078 
 1079 
Figure 3:  Mechanisms of Variant Growth Advantage 1080 
A variety of mechanisms can be envisaged by which variant cells could gain a growth 1081 
advantage over wild type cells.  Cell autonomous mechanisms: mutation (a) drives faster 1082 
cell cycle, or (b) blocks differentiation, or (c) blocks apoptosis.  Cell interactive 1083 
mechanisms: mutation (d) causes variant cell to inhibit the growth of its wild-type 1084 
counterpart (Price et al., 2019) or (e) alters the patterns of differentiation.  The latter could 1085 
generate a selective advantage either if certain differentiated derivatives produced factors 1086 
that promote differentiation (advantage would derive from blocking such lineages) or 1087 
produced factors that blocked general differentiation (advantage would derive from 1088 
enhancing differentiation to such lineages). 1089 
 1090 
Figure 4:  Overview of the origins of mutation in human PSC.  a) Somatic cellular 1091 
proliferation occurs predominantly without replication stress, allowing for faithful cell division. 1092 
However, should replication stress occur, somatic cells can respond with cellular 1093 
senescence, apoptosis or DNA repair. b)  Human pluripotent stem cells proliferate rapidly 1094 
and are susceptible to replication stress, DNA damage and mitotic errors. However, they 1095 
display a low mutation rate, which is reconciled by responding to genetic stresses with 1096 
apoptosis and efficient DNA repair. c) Culture of human PSC with exogenous nucleoside 1097 
alleviates replication stress, DNA damage and mitotic errors. Alleviating genetic stress 1098 
minimises apoptosis, enhancing growth rate and removing the selective advantage of anti-1099 
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BOX 1.   Detection of Genetically Variant Cells 1105 
Routine monitoring of PSC cultures for the appearance of genetic variants is essential: the proportion 1106 
of some common variants in a culture can rise from undetectable to 100% within 5 -10 passages 1107 
(Olariu et al., 2010).  Different screening methods have different advantages and limitations, 1108 
including the minimum proportions of variant cells that can be detected in mosaic populations, and 1109 
whether prior knowledge of the variant to be detected is required.  Other factors to consider are the 1110 
types of variant detectable, cost, speed and whether specialist facilities and expertise are required.  1111 
At a minimum we would recommend regular screening of cultures for common variants using the 1112 
PCR method, which is rapid and can easily be carried out in most laboratories, backed up at key 1113 
decision points in specific experiments with more in-depth analysis using other methods as 1114 
appropriate.   1115 
• Karyotyping by G banding: Indiscriminate view of structural and numerical chromosomal 1116 
abnormalities greater than 5Mb (Steinemann et al., 2013).  Limited to analysis of proliferating 1117 
cells, but the only convenient method to detect balanced genomic rearrangements.  1118 
Sensitivity and precision can be enhanced by use of fluorescent hybridization probes.  1119 
Minimum mosaicism detected: 18% (routine analysis of 30 metaphase spreads), 6% 1120 
(analysis of 100 metaphase spreads) (Baker et al., 2016). 1121 
• Array Comparative Genome Hybridisation (aCGH) and SNP array: Global screening 1122 
detects copy number variants down to 1Kb.  Minimum mosaicism detected: 10-15% for small 1123 
copy number variants.  (Valli et al., 2011). 1124 
• Interphase Fluorescent In Situ Hybridisation (FISH): Hybridisation of fluorescent probes 1125 
to highly complementary nucleic acid sequences in interphase cells.  Requires prior 1126 
knowledge of the copy number variant to be detected.  The presence of false negatives 1127 
dependent upon the type of variant restricts the sensitivity of detection:  Minimum mosaicism 1128 
detected depends upon the number of nuclei assessed and the size of the CNV:  ~5% is 1129 
possible for gains of whole chromosome arms, with 100 nuclei assessed, but this falls 1130 
markedly for smaller CNV (Baker et al., 2016). 1131 
• qPCR based assays:  Rapid method suitable for any well-equipped molecular cell biology 1132 
laboratories.  Requires prior knowledge of the CNV to be detected.  Minimum mosaicism 1133 
detected:  ~5% (Baker et al., 2016). 1134 
• Expression karyotyping: Regions of CNV are detected based on their global gene 1135 
expression from RNA-seq data in comparison to a diploid calibrator sample. Requires no 1136 
prior knowledge of the CNV to be detected, although it is only capable of detecting 1137 
chromosomal aberrations greater than ~10Mb with a sensitivity of ~30% (Mayshar et al., 1138 
2010).    1139 
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• eSNP Karyotyping: An adaptation of expression karyotyping with allele bias. This approach 1140 
does not require a diploid calibrator sample for CNV detection. Resolution of eSNP 1141 
karyotyping depends on the genomic region and sequencing depth, yet it comfortably 1142 
detected amplifications to entire chromosomes or chromosome arms. The eSNP 1143 
karyotyping approach shows comparable sensitivity to other DNA based array approaches 1144 
(~30%) (Weissbein et al., 2016). 1145 
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Chromosome 1q 1172 
• Typically acquired as a structural chromosome rearrangement (unbalanced translocation or 1173 
interstitial duplication) (Amps et al., 2011, Baker et al., 2016) 1174 
• Minimal region: 1q25-q41 (Baker et al., 2016) 1175 
• Potential driver gene: MDM4 1176 
• Association with cancer: Wilms’ tumor (Chagtai et al., 2016), multiple myeloma (Walker et 1177 
al., 2010) and intracranial ependymomas (Kilday et al., 2012) 1178 
 1179 
Chromosome 12p 1180 
• Typically acquired as a whole chromosome trisomy, although a number of studies have also 1181 
reported a partial trisomy of the short arm of chromosome 12 (Amps et al., 2011, Baker et 1182 
al., 2016)  1183 
• Minimal region: 12p11-pter (Baker et al., 2016) 1184 
• Potential driver gene: NANOG 1185 
• Functional consequences observed to date: increased proliferation rate due to increased 1186 
replication, reduced propensity for spontaneous differentiation and apoptosis (Ben-David et 1187 
al., 2014) 1188 
• Association with cancer: testicular germ cell tumors (Atkin and Baker, 1982) 1189 
 1190 
Chromosome 17q 1191 
• Typically acquired as a structural chromosome rearrangement (unbalanced translocation or 1192 
interstitial duplication) (Amps et al., 2011, Baker et al., 2016) 1193 
• Minimal region: 17q25-qter (Baker et al., 2016) 1194 
• Potential driver gene: SURVIVIN (BIRC5) 1195 
• Functional consequences observed to date: growth advantage in undifferentiated cultures 1196 
(Olariu et al., 2010) due to enhanced proliferation (Lee et al., 2015); faster differentiation to 1197 
mesodiencephalic dopaminergic neural cells compared with wild-type cells (Lee et al., 1198 
2015) 1199 
• Association with cancer: testicular germ cell tumors (Kraggerud et al., 2002) and 1200 
neuroblastoma (Bown et al., 2001) 1201 
 1202 
Chromosome 20q 1203 
• Typically acquired as an interstitial duplication (Amps et al., 2011) 1204 
• Minimal region: 20q11.21 (Amps et al., 2011) 1205 
• Driver gene: BCL2L1 (Avery et al., 2013, Nguyen et al., 2013) 1206 
• Functional consequences observed to date: growth advantage due to reduced propensity 1207 
for apoptosis (Avery et al., 2013, Nguyen et al., 2013), reduced dependence on bFGF 1208 
(Werbowetski-Ogilvie et al., 2009), delayed differentiation to neural lineages (Werbowetski-1209 
Ogilvie et al., 2009) and reduced efficiency of neuroectodermal lineage commitment 1210 
(Markouli et al., 2019) 1211 





Chromosome 10p 1217 
• Typically acquired as an interstitial deletion (Amps et al., 2011) 1218 
• Minimal region: 10p13-pter (Amps et al., 2011, Baker et al., 2016) 1219 
• Association with cancer: melanoma (Robertson et al., 1999) and glioblastoma (Kimmelman 1220 





Chromosome 18q 1224 
• Typically acquired as an interstitial deletion (Amps et al., 2011) 1225 
• Minimal region: 18q21-qter (Amps et al., 2011, Baker et al., 2016) 1226 
• Association with cancer: colorectal carcinoma (Popat and Houlston, 2005) 1227 
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